7 Hills Pharma Safely Doses First Patient in Phase 1b/2a Clinical Trial Testing Alintegimod ...
7 Hills Pharma announced their first cancer patient has been safely dosed with alintegimod, an integrin-targeted agonist. The multicenter Phase 1b/2a study is supported by awards from the Cancer Prevention and Research Institute of Texas and the National Cancer Institute. Alintegimod leverages a novel mechanism to enhance immune cell trafficking and T cell activation.
Related Clinical Trials
Highlighted Terms
Related News
7 Hills Pharma safely dosed their first cancer patient with alintegimod, an integrin-targeted agonist, in a multicenter Phase 1b/2a study supported by $15.4 million in awards. Alintegimod aims to enhance T cell activation and trafficking in immune checkpoint inhibitor-resistant patients, leveraging a novel mechanism of action for immune cell trafficking and T cell activation.
7 Hills Pharma announced their first cancer patient has been safely dosed with alintegimod, an integrin-targeted agonist. The multicenter Phase 1b/2a study is supported by awards from the Cancer Prevention and Research Institute of Texas and the National Cancer Institute. Alintegimod leverages a novel mechanism to enhance immune cell trafficking and T cell activation.